SCHEMBL197869

SCHEMBL197869

Brc1ccc2nccnc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.56
CYP1A2 P05177 1/20 0.56
CYP2C19 P33261 1/20 0.56
PABPC1 P11940 1/20 0.43
CCNB2 O95067 1/20 0.42
CDK1 P06493 1/20 0.42
CCNB1 P14635 1/20 0.42
GSK3A P49840 1/20 0.42
GSK3B P49841 1/20 0.42
CCNB3 Q8WWL7 1/20 0.42
ALK Q9UM73 1/20 0.42
MAPT P10636 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
BACE1 P56817 2/20 0.41
EGFR P00533 1/20 0.41
SLC22A12 Q96S37 2/20 0.41
TGFBR1 P36897 1/20 0.40
NCF1 P14598 1/20 0.40
CHEK1 O14757 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29987161 0.84 HTT (0.47) HTTCYP1A2CYP2C19PABPC1CCNB2
SCHEMBL28265822 0.81 GSK3B (0.50) HTTCYP1A2CYP2C19CCNB2CDK1
SCHEMBL28823329 0.73 SLC22A12 (0.53) HTTCYP1A2CYP2C19ALKMAPT
SCHEMBL8337311 0.72 NPC1 (0.52) GSK3BTGFBR1FLT3NPC1RAB9A
SCHEMBL28634341 0.72 PABPC1 (0.58) HTTCYP1A2CYP2C19PABPC1MAPT
SCHEMBL483060 0.72 PABPC1 (0.58) HTTCYP1A2CYP2C19PABPC1MAPT
SCHEMBL30179258 0.72 PABPC1 (0.58) HTTCYP1A2CYP2C19PABPC1MAPT
SCHEMBL14690611 0.72 SLC22A12 (0.51) HTTCYP1A2CYP2C19ALKMAPT
SCHEMBL4470963 0.72 ALK (0.53) HTTCYP1A2CYP2C19ALKMAPT
SCHEMBL197009 0.72 PABPC1 (0.47) HTTCYP1A2CYP2C19PABPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 447 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102797043-B Medicinal molecular fragment library and construction process thereof Tianli (Tianjin) Technology Co., Ltd. (CN) 2015-11-25 CN claimed
CN-102797043-A Medicinal molecular fragment library and construction method thereof CBB NETWORK CO LTD 2012-11-28 CN claimed
EP-4735114-A1 SUBSTITUTED THIENO [3,2-B]PYRIDINES AS INHIBITORS OF PROTEIN KINASES Masarykova Univerzita (CZ) 2026-05-06 EP disclosed
CN-121931199-A Method for synthesizing quinoxaline and derivative thereof by using chemical enzyme synergistic catalytic system 南京工业大学 2026-04-28 CN disclosed
EP-4720040-A1 SULFONAMIDE COMPOUNDS BENEFICIAL IN NEUROPROTECTIVE TREATMENT Lario Therapeutics Limited (GB) 2026-04-08 EP disclosed
EP-4694889-A1 COMPOUNDS AND METHODS FOR TREATING PROTEIN AGGREGATION DISEASES Acelot, Inc. (US) 2026-02-18 EP disclosed
EP-4678632-A1 METHOD FOR PRODUCING ARYL COMPOUND CONTAINING TRITYLSULFANYL GROUP AGC Inc. (JP) 2026-01-14 EP disclosed
US-20250346557-A1 METHOD FOR PRODUCING ARYL COMPOUND CONTAINING TRITYLSULFANYL GROUP AGC Inc. (JP) 2025-11-13 US disclosed
US-12435128-B2 Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 TAIHO PHARMACEUTICAL CO., LTD. (JP) 2025-10-07 US disclosed
EP-3600294-B1 TRI-SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF BETA AND METHODS OF TREATMENT CLAVIUS PHARMACEUTICALS LLC (US) 2025-09-03 EP disclosed
US-20250223291-A1 IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS INCYTE CORPORATION 2025-07-10 US disclosed
WO-2000062767-A2 PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDINE OR PYRIMIDINE DERIVATES FOR INHIBITION OF CYTOKINE PRODUCTION AND SECRETION TARGACEPT, INC. (US) 2000-10-26 WO disclosed
WO-2000063224-A2 MACROLIDE ANTIINFECTIVE AGENTS KOSAN BIOSCIENCES, INC. (US) 2000-10-26 WO disclosed
WO-2000062783-A2 KETOLIDE ANTIBACTERIALS ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2000-10-26 WO disclosed
EP-1042274-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE R.J. REYNOLDS TOBACCO COMPANY (US) 2000-10-11 EP disclosed
WO-2000023418-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE R.J. REYNOLDS TOBACCO COMPANY (US) 2000-04-27 WO disclosed
CN-1237183-A 6-0-substituted ketolides with antibacterial activity ABBOTT CO (US) 1999-12-01 CN disclosed
EP-0929563-A1 6-O-SUBSTITUTED KETOLIDES HAVING ANTIBACTERIAL ACTIVITY Abbott Laboratories (US) 1999-07-21 EP disclosed
US-5866549-A MACROLIDE ANTIBIOTICS ABBOTT LABORATORIES (US) 1999-02-02 US disclosed
WO-1998009978-A1 6-O-SUBSTITUTED KETOLIDES HAVING ANTIBACTERIAL ACTIVITY ABBOTT LABORATORIES (US) 1998-03-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12435128-B2 Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 INMT, CARM1, KDM1B HTT 4089/4885CYP1A2 1947/4885CYP2C19 3289/4885
US-20250223291-A1 IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS ERBB2, MERTK, ABL1 HTT 3704/4885CYP1A2 1641/4885CYP2C19 1787/4885
US-20250346557-A1 METHOD FOR PRODUCING ARYL COMPOUND CONTAINING TRITYLSULFANYL GROUP STS, TST, CYP3A5 HTT 2401/4885CYP1A2 43/4885CYP2C19 210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.